DHR vs TECH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHR and TECH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHR and TECH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

Bio-Techne Corporation is a global life-sciences tools and diagnostics company based in Minnesota. It supplies the reagents, proteins, antibodies, immunoassays, and analytical instruments that biopharma and academic researchers use in drug discovery, cell and gene therapy, and diagnostics. The portfolio spans three customer-facing brands (R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics) and is reported in two segments: Protein Sciences, the larger piece at roughly three-quarters of revenue, and Diagnostics and Spatial Biology, roughly the remaining quarter. Because it sells the consumables and instruments that sit upstream of research and manufacturing, Bio-Techne's results track biopharma and academic funding cycles rather than any single end product, with growth pockets in GMP proteins for cell therapy and its COMET spatial-biology platform.

Full TECH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
• TECH drivers: Pending Merck KGaA acquisition; Spatial biology and higher-value platforms.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s), leaving little room for disappointment. For TECH, the central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from regulatory objections, the shareholder vote, or a change in conditions) could send shares back toward pre-announcement levels, while the upside above the deal price is limited.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DHR if you believe its drivers more; TECH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHR and TECH guides.

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, while adjusted EPS grew faster on margins and buybacks. The stock has typically carried a premium valuation, with a trailing P/E in the mid-30s to mid-40s and a forward P/E closer to the low 20s as estimates rise. Figures are approximate and as of JULY 2026.

TECH. Figures are approximate and tied to the asOf date; verify live numbers and the current status of the Merck KGaA transaction before acting. Because the stock trades near the $73 cash offer, traditional valuation multiples matter less than the merger: the return an investor earns from here is largely the spread between the market price and the deal price, adjusted for the odds and timing of closing. If the deal completes, holders receive $73 per share in cash; if it breaks, the stock would re-rate to standalone fundamentals.

Headline figures (approximate, JULY 2026): DHR shows revenue (fy2025) ~$24.6B, adj. diluted eps (fy2025) ~$7.80, free cash flow (fy2025) ~$5.3B, 2026 adj. eps guidance ~$8.35 to $8.55; TECH shows situation Pending acquisition by Merck KGaA at $73 per share in cash (announced June 25, 2026); verify live figures and deal status before acting, enterprise value of deal ~$11.3 billion, roughly a 36% premium to the prior one-month average price, recent share price Trading near the low $70s, close to the cash offer, which caps upside and signals the market is pricing deal completion, market cap ~$11 billion (approximate; moves with the deal spread).

DHR and TECH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DHR and TECH exposure against your real portfolio. It is not an investment adviser.